Logo
x

Search

Subscribe Now

ipsen

Ipsen’s Kayfanda (Odevixibat) Gains the CHMP’s Positive Opinion to Treat Cholestatic Pruritus in Alagille Syndrome (ALGS)

Ipsen’s Kayfanda (Odevixibat) Gains the CHMP’s Positive Opinion to Treat Cholestatic Pruritus in Alagille Syndrome (ALGS)

  • July 26, 2024
Ipsen’s Iqirvo (Elafibranor) Gains the CHMP’s Positive Opinion for Treating Primary Biliary Cholangitis (PBC)

Ipsen’s Iqirvo (Elafibranor) Gains the CHMP’s Positive Opinion for Treating Primary Biliary Cholangitis (PBC)

  • July 26, 2024
Ipsen Collaborates with Day One Biopharmaceuticals for the commercialization of Tovorafenib to Treat Pediatric Low-Grade Glioma

Ipsen Collaborates with Day One Biopharmaceuticals for the commercialization of Tovorafenib to Treat Pediatric Low-Grade Glioma

  • July 25, 2024
Ipsen Teams Up with Foreseen Biotechnology to Develop FS001 for Solid Tumors

Ipsen Teams Up with Foreseen Biotechnology to Develop FS001 for Solid Tumors

  • July 11, 2024
Ipsen Reports Collaboration Expansion with Exelixis to Develop Cabometyx for Treating Neuroendocrine Tumors

Ipsen Reports Collaboration Expansion with Exelixis to Develop Cabometyx for Treating Neuroendocrine Tumors

  • July 2, 2024
Ipsen’s Iqirvo (Elafibranor) Gains the US FDA’s Accelerated Approval for Treating Primary Biliary Cholangitis

Ipsen’s Iqirvo (Elafibranor) Gains the US FDA’s Accelerated Approval for Treating Primary Biliary Cholangitis

  • June 11, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.